Background {#Sec1}
==========

Late cardiotoxicity is a known complication of anthracycline therapy. CMR is the gold standard for assessment of cardiac function, with demonstrated utility in the detection of subtle abnormalities of myocardial structure and motion. Using conventional and novel CMR techniques, we re-examined a cohort of late cancer survivors, previously studied with echocardiography in childhood. We compared them concurrently to healthy controls, aiming to characterise myocardial abnormalities in the context of longitudinal functional data.

Methods {#Sec2}
=======

30 patients exposed to anthracyclines in childhood and 19 age and sex-matched controls underwent conventional functional CMR, T1 mapping, Tissue Phase Mapping (TPM) and detailed echocardiography. Myocardial T1 maps were obtained using a Modified Look-Locker Inversion Recovery (MOLLI) sequence. Native T1 maps were obtained in controls, and patients were given 0.15mmol/kg gadolinium for extracellular volume (ECV) quantification. Respiratory self-gated TPM was performed, using a rotating golden-angle spiral acquisition with retrospective cardiac gating. Both were acquired in the left ventricular (LV) mid-short axis.

Results {#Sec3}
=======

The patients\' mean age was 31 ±5 years and they were studied a median of of 25 (range 16-32) years following a median cumulative anthracycline dose of 220 (range 90-370) mg/m^2^ for either leukaemia or Wilms tumour.

Mid-term fractional shortening (FS), 8 years following therapy had a mean value 33.1 ±5.1%. Current CMR-derived LVEF was normal, although reduced compared to controls (61% ±6 vs. 65% ±5, p \<0.01) and correlated negatively with cumulative anthracycline dose (R^2^ 0.26, p \<0.01) and positively with mid-term FS (R^2^ 0.27, p \<0.03).

Native myocardial T1 was not significantly different, comparing patients and controls (967 ±37 vs. 960 ±37, p 0.53). Mean ECV was 0.26 ±0.04 and was higher in patients receiving cumulative doses of \>300mg/m^2^ (0.25 ±0.02 vs. 0.28 ±0.05, p = 0.02).

TPM-derived LV radial, longitudinal and tangential systolic velocities, and longitudinal E/A ratio were not significantly reduced compared to controls.

Conclusions {#Sec4}
===========

This is the first detailed assessment of myocardial function using novel CMR techniques in survivors, 25 years following childhood anthracycline therapy. Mild, asymptomatic, dose-related reduction in LVEF is seen, with no associated change in native T1 values. Increased ECV is seen only at cumulative doses \>300mg/m^2^. Previous studies have shown significantly increased ECV, a median of 8 years post therapy. Our finding, associated with detailed myocardial motion analysis, provides further insight into the mechanisms of long-term remodeling in this specific cohort.
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Registered charity no. 298405.Table 1Control and Patient group characteristics and cardiovascular MR dataVARIABLECONTROL (n = 19)PATIENTS (n = 30)p valueFemale n (%)10 (53)17 (57)0.86Current Age (years)32 (26-39)32 (23-42)0.96Height (cm)171 ±6.3169 ±9.20.3Weight (kg)67 ±875 ±210.1NYHA I / II19 (100) / 0 (0)28 (93) / 2 (7)0.44Systolic BP (mmHg)120 ±10123 ±150.46Diastolic BP (mmHg)73 ±775 ±110.6AML n (%)2 (7)ALL n (%)23 (77)Wilms n (%)5 (17)Age at diagnosis (years)4.6 (1-15)Time since chemo (years)25 (16-32)Anth Dose (mg/m2)220 (90-370)Radiotherapy n (%)24 (80)BMT n (%)7 (23)CARDIOVASCULAR MR DATALVEDV index (ml/m2)72 ±873 ±120.92LVESV index (ml/m2)25 ±630 ±8\*0.05LV EF (%)65 ±561 ±6\*0.01LV mass index (g/m2)60 ±1058 ±110.53RVEDV index (ml/m2)76 ±869 ±120.10RVESV index (ml/m2)29 ±628 ±140.68RV EF (%)62 ±463 ±50.39MAPSE (cm)15 ±1.113 ±2.6\*0.02Left Atrial Area (cm2)20 ±2.321 ±3.10.47Native myocardial T1960 ±37967 ±370.53Native blood pool T11484 ±761463±1180.50Extracellular volume fraction0.26 ±0.04Focal LGE2 (7)Values expressed mean mean ±SD.LVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; LVEF = left ventricular ejection fraction; RVEDV = right ventricular end diastolic volume; RVESV = right ventricular end systolic volume; RVEF = right ventricular ejection fraction; MAPSE = mitral annular plane systolic excursion; LGE = Late gadolinium enhancement.Table 2Data comparing high and low cumulative anthracycline dose.CARDIOVASCULAR MR DATALow dose \<300mg/m2 (n =22)High dose \>300mg/m2 (n = 8)p ValueLVEDV index (ml/m2)71 ±1180 ±140.1LVESV index (ml/m2)28 ±836 ±6\*0.03LV EF (%)65 ±554 ±6\*0.01LV Mass index (g/m2)58 ±1159 ±90.94RVEDV index (ml/m2)70 ±1069 ±170.87RVESV index (ml/m2)28 ±1526 ±70.77RV EF (%)65 ±562 ±20.46MAPSE (cm)13 ±2.113 ±4.10.72Left Atrial Area (cm2)21 ±321 ±40.94Native T1960 ±39992 ±24\*0.05Native blood pool T11464 ±791527±38\*0.05Extracellular volume fraction0.25 ±0.020.28 ±0.05\*0.02LGE1 (14)1 (5)Values expressed mean mean ±SDLVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; LVEF = left ventricular ejection fraction; RVEDV = right ventricular end diastolic volume; RVESV = right ventricular end systolic volume; RVEF = right ventricular ejection fraction; MAPSE = mitral annular plane systolic excursion; LGE = Late gadolinium enhancement
